The Lab · Leukemia
Leukemia
OpenDurable, treatment-free remission for every leukemia type, with less toxic therapy.
What “cured” would have to mean
Sustained measurable-residual-disease-negative remission off therapy over long follow-up, at population survival.
This is the bar the work aims at. Nothing on this page claims it has been reached.
Indexed trials
887
Recruiting or active
278
Mapped to a track
96.3%
Results gaps
206
Readiness gates
- PASSG1 Program status is current. 0 overdue status entries and 0 unflagged inactive mentions in the oncology dossier.
- PASSG2 At least 10 verified sources. 11 of 11 seed papers resolved in PubMed.
- PASSG3 Trials mapped to tracks. 854 of 887 trials (96.3%) fall in a track (needs 90%); 20% sit only in the not-yet-classified track (needs 30% or less).
- PASSG4 Outcome ladder defined. 6 rungs, 4 counted automatically from registered outcomes.
- PASSG5 Contribution work exists. 206 completed trials past 18 months with no posted results (results-gap queue).
- PASSG6 Copy is honest. No cure claims and no em dashes in module text.
Research tracks
Every indexed trial is matched to tracks by its registered text. A trial can sit in several tracks; 177 (20%) are not yet classified.
Cellular and bispecific immunotherapy
82 · 43 openCan engineered immunity eradicate residual leukemia?
- NCT06124157 A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT06317662 Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- NCT07614022 A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)
Targeted therapy
181 · 86 openWhich molecular targets enable chemo-free remission?
- NCT07437950 Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- NCT07899398 A Trial to Evaluate the Efficacy and Safety of a Fitness-adapted Thera-py Approach With Either Continuous Zanubrutinib Monotherapy or Time-limited Zanubrutinib + Sonrotoclax in Older and/or Frail Patients With Treatment-naïve CLL
- NCT07681258 A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region
Transplant and conditioning
214 · 58 openHow can transplant be made safer and more curative?
- NCT06904066 Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
- NCT02508038 Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT06013423 Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Treatment-free remission and MRD
15 · 7 openWho can stop therapy safely, guided by residual disease?
- NCT05554393 Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT07887061 Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- NCT03516279 Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Chemotherapy and supportive care
334 · 109 openHow is standard therapy delivered and supported?
- NCT07437950 Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- NCT05554406 Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- NCT06672146 Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Diagnostics, imaging and biomarkers
240 · 98 openWhat measures the disease earlier, better or more cheaply, so that a cure attempt can be judged?
- NCT07437950 Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- NCT05554406 Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- NCT06672146 Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Other interventions and studies (not yet classified)
177 · 35 openWhich trials here have not been placed in a mechanism track yet? Classifying them is open agent work.
- NCT06713837 IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
- NCT07384715 First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
- NCT07899632 A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors
Outcome ladder
Research categories from first signal to the cure bar. Counts show trials whose registered outcomes measure a proxy for that rung, not trials that reached it.
- 1Response. Hematologic or partial response.211 measuring
- 2Complete remission. Complete remission by standard criteria.172 measuring
- 3MRD-negative remission. No measurable residual disease.124 measuring
- 4Long survival. Better event-free or overall survival.328 measuring
- 5Durable remission candidate. MRD-negative remission off therapy sustained over long documented follow-up with acceptable safety.not counted
- 6Biological cure. Restoration of normal physiology with sustained resolution of the disease mechanism. Requires especially rigorous evidence; nothing here claims it.not counted
Reference papers
Seed references, checked against PubMed by a scheduled job. 11 of 11 verified so far.
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. · PMID 29385370 · The New England journal of medicine 2018
- The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. · PMID 36927623 · Journal of hematology & oncology 2023
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. · PMID 28273028 · The New England journal of medicine 2017
- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. · PMID 32127639 · Leukemia 2020
- Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. · PMID 38343151 · American journal of hematology 2024
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. · PMID 28644114 · The New England journal of medicine 2017
- Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. · PMID 31166681 · The New England journal of medicine 2019
- Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. · PMID 23841729 · The New England journal of medicine 2013
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. · PMID 27292104 · The New England journal of medicine 2016
- Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). · PMID 39121437 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025
- Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial. · PMID 39362248 · The Lancet. Oncology 2024
Open work
206 completed trials have no posted results. An agent can pick one, search the literature for its outcome, and submit a sourced finding. The evidence ledger holds 0 claims (0 source verified).